☆ 4.6 Article

Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Dermatology

Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor- Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model

Jana Jandova et al.

Summary: This study reveals that BRAFi treatment exacerbates the upregulation of epithelial-to-mesenchymal transition (EMT) genes in BRAFV600E/NRASQ61K cells, promoting invasiveness and metastasis. These findings have potential implications for the treatment of NRAS-driven BRAFi-resistant tumors.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection

Review Oncology

Novel adjuvant options for cutaneous melanoma

F. Dimitriou et al.

Summary: This review discusses the latest clinical trial data, current treatment landscape, and future progress for the management of resected stage IIIB-IIID melanoma. Adjuvant therapy with immunotherapy or targeted therapy is recommended for improving recurrence-free survival in high-risk melanoma patients.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Oncology

Advances in Targeting Cutaneous Melanoma

Dimitri Kasakovski et al.

Summary: Cutaneous Melanoma (CM) is an aggressive cancer originating from pigment-producing melanocytes in the skin, with high metastatic potential. Although it represents a small fraction of skin cancers, it accounts for most skin-cancer-related deaths globally. Immune checkpoint inhibition has been a significant therapeutic approach, but challenges such as the immunosuppressive tumor microenvironment and treatment resistance persist. Combining local and systemic treatments can enhance therapeutic response and overcome resistance, yet complex drug combinations may increase the risk of immune-related adverse events.

CANCERS (2021)

Add to Collection

Article Oncology

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

Yujue Wang et al.

Summary: Rationally sequencing and combining PD-1/L1 and MAPK-targeted therapies may overcome innate and acquired resistance. Comparative analysis of different treatment regimens can optimize therapeutic efficacy for melanoma and colorectal and pancreatic carcinoma.

CANCER CELL (2021)

Add to Collection

Article Oncology

Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence

Elisabetta Grillo et al.

Summary: The activation of VEGFR2(R1051Q) mutation leads to metabolic changes in melanoma cells, resulting in increased energy metabolism and dependence on glutamine. This highlights a metabolic vulnerability in tumors with this mutation and suggests novel therapeutic approaches.

CANCER LETTERS (2021)

Add to Collection

Article Medicine, General & Internal

Immune checkpoint inhibitors in melanoma

Matteo S Carlino et al.

LANCET (2021)

Add to Collection

Review Medicine, General & Internal

Recent Advances in the Treatment of Melanoma

Brendan D. Curti et al.

Summary: Improvements in management have led to increased survival rates for melanoma, with advances such as sentinel-node sampling and targeted therapy reducing morbidity and enhancing treatment outcomes for advanced disease.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism

Hyelim Cho et al.

Summary: Three limonoid natural products were found to have selective anti-proliferative activity against melanoma cell lines dependent on BRAF(V600E) and NRAS(Q61K) mutations. Transcriptome analysis revealed a dependency on the expression of mitochondrial cytochrome P450 oxidase CYP27A1, a transcriptional target of MITF. These compounds target mitochondrial biogenesis and inhibit tumor bioenergetics through a covalent mechanism, offering a strategy for melanoma-specific targeting.

CELL CHEMICAL BIOLOGY (2021)

Add to Collection

Review Oncology

Cancer metabolism: looking forward

Inmaculada Martinez-Reyes et al.

Summary: This Perspective discusses the main themes in cancer metabolism research, focusing on the relationship between tumour initiation and progression with metabolic reprogramming, as well as the importance of tumor microenvironment and metabolic regulation.

NATURE REVIEWS CANCER (2021)

Add to Collection

Review Oncology

Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy

Xiaoying Sun et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

Marzia Del Re et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Review Oncology

Current state of melanoma diagnosis and treatment

Lauren E. Davis et al.

CANCER BIOLOGY & THERAPY (2019)

Add to Collection

Article Oncology

Serological TK1 predict pre-cancer in routine health screenings of 56,178 people

Yu Wang et al.

CANCER BIOMARKERS (2018)

Add to Collection

Review Chemistry, Multidisciplinary

Cancer Metabolism: Current Understanding and Therapies

Jessica L. Counihan et al.

CHEMICAL REVIEWS (2018)

Add to Collection

Article Oncology

Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients

Shufang Ning et al.

JOURNAL OF CANCER (2018)

Add to Collection

Article Cell Biology

Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis

Xiaole Zhu et al.

CELL PROLIFERATION (2018)

Add to Collection

Article Oncology

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Nusayba Bagegni et al.

BREAST CANCER RESEARCH (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells

Phatchariya Phannasil et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)

Add to Collection

Article Oncology

Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people

Yu Wang et al.

CANCER BIOMARKERS (2016)

Add to Collection

Article Medicine, Research & Experimental

Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation

Katherine Sellers et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

Add to Collection

Review Oncology

Therapeutic Advances and Treatment Options in Metastatic Melanoma

Douglas B. Johnson et al.

JAMA ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Cutaneous melanoma

Alexander M. M. Eggermont et al.

LANCET (2014)

Add to Collection

Review Oncology

Thymidine kinase and cancer monitoring

Stefan Aufderklamm et al.

CANCER LETTERS (2012)

Add to Collection

Article Oncology

Inactivation of the HIF-1α/PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants

Jerome Kluza et al.

CANCER RESEARCH (2012)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Correlation of 18F-FLT uptake with equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in gastrointestinal cancer

Reiko Kameyama et al.

NUCLEAR MEDICINE COMMUNICATIONS (2011)

Add to Collection

Article Oncology

Serum thymidine kinase 1 activity in breast cancer

Benjamin Nisman et al.

CANCER BIOMARKERS (2010)

Add to Collection

Article Oncology

Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas

Zhishan Li et al.

EUROPEAN JOURNAL OF CANCER PREVENTION (2010)

Add to Collection

Article Oncology

Biology of Human Cutaneous Melanoma

Elias Elias et al.

Cancers (2010)

Add to Collection

Article Oncology

Genetic alterations in signaling pathways in melanoma

FG Haluska et al.

CLINICAL CANCER RESEARCH (2006)

Add to Collection

Article Biotechnology & Applied Microbiology

The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody

Q He et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.